“ A pharmaceutical composition for reverting mammalian neoplasia cells of epithelial origin back to a normal differentiation. “
Application published 2006-03-10, filed 2004-02-20
The invention relates to the use of an effective dose of N-acetyl-L-cysteine, or a dimeric form thereof, for the manufacturing of a drug for reverting mammalian neoplasia cells of epithelial origin back to a normal differentiation whereby the abnormal proliferation of the neoplasia cells is reverted to a normal pathway.
Applicant
Nactilus AB.
P.O Box 20047, S-200 74 Malmo, Sweden.
Inventor
1. LUNDEBERG Thomas 2. CONCETTA ROMANO Maria
International Info
Classification: A61K 31/198
Publication Number: WO 02/051405
Application Date: 2001-12-27
Priority Information
0004867-8 Nactilus AB 2000-12-27